Autumn Glory Partners LLC Has $3.66 Million Holdings in Medtronic PLC $MDT

Autumn Glory Partners LLC lifted its position in Medtronic PLC (NYSE:MDT) by 17.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,395 shares of the medical technology company’s stock after buying an additional 5,663 shares during the quarter. Medtronic comprises approximately 1.4% of Autumn Glory Partners LLC’s holdings, making the stock its 13th biggest position. Autumn Glory Partners LLC’s holdings in Medtronic were worth $3,657,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Medtronic by 6.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 241,630 shares of the medical technology company’s stock valued at $21,695,000 after buying an additional 13,973 shares during the period. Petrus Trust Company LTA acquired a new stake in shares of Medtronic in the first quarter valued at approximately $292,000. Ashton Thomas Private Wealth LLC boosted its stake in shares of Medtronic by 12.8% during the 1st quarter. Ashton Thomas Private Wealth LLC now owns 25,471 shares of the medical technology company’s stock worth $2,307,000 after acquiring an additional 2,895 shares during the period. Finally, Fred Alger Management LLC increased its holdings in shares of Medtronic by 33.1% during the 1st quarter. Fred Alger Management LLC now owns 48,994 shares of the medical technology company’s stock worth $4,437,000 after acquiring an additional 12,193 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Medtronic Stock Performance

NYSE MDT opened at $97.32 on Tuesday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $124.77 billion, a P/E ratio of 26.23, a P/E/G ratio of 2.53 and a beta of 0.71. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The firm has a 50-day moving average price of $97.71 and a two-hundred day moving average price of $94.21.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same period last year, the firm earned $1.26 earnings per share. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be issued a $0.71 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s payout ratio is currently 76.55%.

Analyst Upgrades and Downgrades

MDT has been the subject of several research reports. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday. Leerink Partners set a $120.00 target price on shares of Medtronic and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Sanford C. Bernstein set a $111.00 price target on shares of Medtronic in a research note on Wednesday, November 19th. Daiwa Capital Markets increased their price target on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Finally, UBS Group raised their price objective on shares of Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $109.94.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).